In 1616 patients CLINICAL STATEMENTS AND GUIDELINES with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study, hypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold higher mortality rate (both P<0.01) than those seen in normotensive patients with AS, although no impact on progression of valve stenosis lead- ing to symptoms requiring AVR was seen. Medical therapy for hypertension follows standard guide- lines, starting at a low dose and gradually titrating upward as needed to achieve blood pressure con- trol. There are no studies addressing specific anti- hypertensive medications in patients with AS, but diuretics may reduce stroke volume, particularly if the LV chamber is small at baseline. In theory, ACE inhibitors may be advantageous because of the potential beneficial effects on LV fibrosis, in addi- tion to control of hypertension. Consideration should be given to a higher target blood pressure for patients with AS than is recommended for the general population, but this is an underexplored area, and further data are needed before a differ- ent target blood pressure can be recommended for patients with AS.1 3,9 13 2. Concurrent CAD is common in patients with AS, and all patients should be screened and treated for hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of statin therapy for mild to moderate AS, although aortic valve event rates were not reduced, the rate of ischemic events was reduced by about 20% in the statin therapy group even though these patients did not meet standard cri- teria for statin therapy.4 6,14,15 3. 